Literature DB >> 8944372

Neutrophil antibodies (pANCA) in chronic liver disease and inflammatory bowel disease: do they react with different antigens?

F Seibold1, P Weber, A Schöning, H Mörk, S Goppel, M Scheurlen.   

Abstract

OBJECTIVE: A high frequency of perinuclear neutrophil antibodies (pANCA) has been described in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We evaluated the presence of pANCA in chronic liver disease and compared the immunoglobulin G (IgG) subclasses of pANCA in inflammatory bowel disease with chronic liver disease. Since the antigen reacting with pANCA could not be determined, the antigenic role of various neutrophil antigens was evaluated. SUBJECTS AND METHODS: Detection of pANCA and their IgG subclass was performed by immunofluorescence. One hundred and forty patients with chronic liver disease, 96 patients with inflammatory bowel disease and 40 healthy controls were tested for pANCA. pANCA positive and negative sera were evaluated for their reactivity with different neutrophil antigens in an enzyme-linked immunosorbent assay (ELISA) system.
RESULTS: pANCA were found in 8 of 23 patients (35%) with autoimmune hepatitis, in 6 of 21 patients (28%) with primary biliary cirrhosis (PBC), in 18 of 25 patients (72%) with PSC, in 3 of 48 patients (6%) with viral hepatitis, in 30 of 48 patients (62%) with UC, and in 2 of 48 patients (4%) with Crohn's disease. All 20 patients with alcoholic liver disease and 40 healthy controls were negative for pANCA. In contrast to the patients with UC who had 83% IgG1 and only 13% IgG3 antibodies, patients with PSC and PBC had an overexpression of IgG3 antibodies (PSC: 50% IgG3; PBC: 67% IgG3). A proportion of pANCA positive sera recognized lactoferrin, myeloperoxidase, cathepsin G, laminarase and alpha 1-antitrypsin.
CONCLUSION: pANCA is not present only in patients with UC but in autoimmune liver diseases such as PSC, autoimmune hepatitis and PBC. Considering the IgG subclass of pANCA, the antibody response of patients with UC is different from patients with liver disease. No unique pANCA specific antigen could be detected, so heterogeneity of pANCA has to be considered.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8944372     DOI: 10.1097/00042737-199611000-00012

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  8 in total

Review 1.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

Review 2.  Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis.

Authors:  J Franco; K Saeian
Journal:  Curr Gastroenterol Rep       Date:  1999-04

3.  pANCA represents a cross-reactivity to enteric bacterial antigens.

Authors:  F Seibold; S Brandwein; S Simpson; C Terhorst; C O Elson
Journal:  J Clin Immunol       Date:  1998-03       Impact factor: 8.317

Review 4.  Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases.

Authors:  Birgit Terjung; Ulrich Spengler
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

5.  Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations.

Authors:  L J Walker; M C Aldhous; H E Drummond; B R K Smith; E R Nimmo; I D R Arnott; J Satsangi
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

6.  Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease.

Authors:  Frank H Klebl; Frauke Bataille; Ferdinand Hofstädter; Hans Herfarth; Jürgen Schölmerich; Gerhard Rogler
Journal:  Int J Colorectal Dis       Date:  2004-01-27       Impact factor: 2.571

7.  Morbid Sequences Suggest Molecular Mimicry between Microbial Peptides and Self-Antigens: A Possibility of Inciting Autoimmunity.

Authors:  Susanta Pahari; Deepyan Chatterjee; Shikha Negi; Jagdeep Kaur; Balvinder Singh; Javed N Agrewala
Journal:  Front Microbiol       Date:  2017-10-09       Impact factor: 5.640

Review 8.  Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence.

Authors:  Andrew Mertz; Nhu An Nguyen; Konstantinos H Katsanos; Ryan M Kwok
Journal:  Ann Gastroenterol       Date:  2019-01-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.